可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]段卡丹,李裕舒.心房重构和炎症在心房纤颤中的意义[J].心脏杂志,2011,23(5):684-686.
[2]Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the management of atrial Fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)[J].European Heart Journal,2010,31(19):2369-2429.
[3]Lip GY,Nieuwlaat R,Pisters R,et al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation[J].Chest,2010,137(2):263-272.
[4]Pisters R,Lane DA,Nieuwlaat R,et al.A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation: The Euro Heart Survey[J].Chest,2010, 138(5):1093-1100.
[5]Connolly SJ,Pogue J,Hart RG,et al.Effect of clopidogrel added to aspirin in patients with atrial fibrillation[J].N Engl J Med,2009,360(20):2066-2078.
[6]Ruiz-Nodar JM,Marín F,Hurtado JA,et al.Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneons coronary intervention and stent implantation implications for bleeding risk and prognosis[J].J Am Coll Cardiol,2008,51(8):818-825.
[7]S rensen R,Hansen ML,Abildstrom SZ,et al.Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin,clopidogrel,and vitamin K antagonists in Denmark:a retrospective analysis of nationwide registry data[J].Lancet,2009,374(9706):1967-1974.
[8]Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J].Ann Intern Med,2007,146(12):857-867.
[9]Paikin JS,Wright DS,Crowther MA,et al.Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents[J].Circulation,2010,121(18):2067-2070.
[10]何 华,马长生.是什么阻碍了我们应用华法林 [J].中国医刊,2008,48(8):4-5.
[11]熊建忠,邱 光,王心宇,等.华法林在房颤患者中的使用现状及合理应用[J].中西医结合心脑血管病杂志,2009,7(10):1233-1234.
[12]胡 凯,葛均波.心房颤动患者脑卒中预防研究进展[J].上海医学,2009,32(1):9-10.
[13]ROCKET AF Study Investigators.Rivaroxaban-Once daily,oral,direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study[J].Am Heart J,2010,159(3):340-347.
[14]Wallentin L,Yusuf S,Ezekowitz MD,et al.Efficacy and safety of dabigatran compared with warfarin at diff erent levels of international normalised ratio control for stroke prevention in atrial fi brillation: an analysis of the RE-LY trial[J].Lancet,2010, 376(9745):975-983.